{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:08:35Z","timestamp":1770329315227,"version":"3.49.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jcf.2023.03.005","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T15:32:10Z","timestamp":1701358330000},"page":"68-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["How representative are clinical trial cohorts of the general CF population? Implications for trial planning"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-0988","authenticated-orcid":false,"given":"Rebecca","family":"Dobra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Pinnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Madge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1705-4780","authenticated-orcid":false,"given":"Nicholas J","family":"Simmonds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3506-1199","authenticated-orcid":false,"given":"Jane C","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2023.03.005_bib0001","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00406-004-0547-5","article-title":"How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials?","volume":"255","author":"Riedel","year":"2005","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.jcf.2023.03.005_bib0002","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1164\/rccm.200502-273OC","article-title":"Clinical trial participants compared with nonparticipants in cystic fibrosis","volume":"173","author":"Goss","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2023.03.005_bib0003","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/humu.10041","article-title":"Cystic fibrosis: a worldwide analysis of CFTR mutations - Correlation with incidence data and application to screening","volume":"19","author":"Bobadilla","year":"2002","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.jcf.2023.03.005_bib0004","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation","volume":"187","author":"Davies","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2023.03.005_bib0005","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of Elexacaftor\/Tezacaftor\/Ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a Phase 3b, randomized, placebo-controlled study","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2023.03.005_bib0006","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S2213-2600(16)30121-7","article-title":"Efficacy and safety of lumacaftor\/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis","volume":"4","author":"Elborn","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2023.03.005_bib0007","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","article-title":"Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor","volume":"73","author":"Bessonova","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2023.03.005_bib0008","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jcf.2021.03.021","article-title":"Guiding the rational design of patient-centred drug trials in Cystic Fibrosis: a Delphi study","volume":"20","author":"Dobra","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.03.005_bib0009","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.jcf.2019.04.008","article-title":"Who and why; sharing our experiences of developing a standard operating procedure (SOP) to allocate screening slots for highly competitive cystic fibrosis trials","volume":"18","author":"Dobra","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.03.005_bib0010","doi-asserted-by":"crossref","unstructured":"Dobra, R. et\u00a0al. Optimising equity of access: how should we allocate slots to the most competitive trials in Cystic Fibrosis (CF)? 20, 978\u201385 (2021).","DOI":"10.1016\/j.jcf.2021.03.027"},{"key":"10.1016\/j.jcf.2023.03.005_bib0011","unstructured":"HIT-CF | European Cystic Fibrosis Society (ECFS). https:\/\/www.ecfs.eu\/hit-cf."},{"key":"10.1016\/j.jcf.2023.03.005_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.106878","article-title":"Who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies","volume":"199","author":"Desai","year":"2022","journal-title":"Respir Med"},{"key":"10.1016\/j.jcf.2023.03.005_bib0013","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/ppul.25285","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2023.03.005_bib0014","first-page":"1721","article-title":"Minorities are underrepresented in clinical trials of pharmaceutical agents for cystic fibrosis","volume":"13","author":"McGarry","year":"2016","journal-title":"Ann Am Thorac Soc"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323000693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T04:11:55Z","timestamp":1767240715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323000693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1569199323000693"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.03.005","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How representative are clinical trial cohorts of the general CF population? Implications for trial planning","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}